We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
+31.47%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.7B
AUM Growth
-$294M
Cap. Flow
-$772M
Cap. Flow %
-28.57%
Top 10 Hldgs %
31.56%
Holding
109
New
24
Increased
20
Reduced
34
Closed
23

Top Buys

Rank Stock Value
1
ATEC icon
Alphatec Holdings
ATEC
+$39.7M
2
HUM icon
Humana
HUM
+$32.6M
3
MAZE
Maze Therapeutics
MAZE
+$29.9M
4
AVTX icon
Avalo Therapeutics
AVTX
+$25.8M
5
ALMR
Alamar Biosciences
ALMR
+$24.5M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$78.9M
2
NUVL
Nuvalent
NUVL
+$71.8M
3
CGON icon
CG Oncology
CGON
+$66.7M
4
ARGX icon
argenx
ARGX
+$55.5M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$46.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.44%
2 Miscellaneous 3.68%
3 Financials 0.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
101
Revolution Medicines
RVMD
$44.6B
– –
-84,900
Closed -$8.26M
RVTY icon
102
Revvity
RVTY
$14.4B
– –
-48,400
Closed -$4.24M
SLNO
103
DELISTED
Soleno Therapeutics
SLNO
– –
-959,259
Closed -$32.1M
TARS icon
104
Tarsus Pharmaceuticals
TARS
$3.15B
– –
-265,715
Closed -$18.6M
TGTX icon
105
TG Therapeutics
TGTX
$8.26B
– –
-358,800
Closed -$11.9M
GRAL
106
GRAIL Inc
GRAL
$3.57B
– –
-142,755
Closed -$7.38M
1 2 3 4
5

Similar funds

CWM
Connecticut Wealth Management Farmington, Connecticut $2.7B AUM 21.91% 1-Year Est. Return
M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM

Braidwell's Q2 2026 Portfolio in Review

As of Q2 2026, Braidwell held 109 positions worth $2.7B, down 9.8% from $3B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Braidwell withdrew a net $772M in Q2 2026, closing 23 positions and reducing 34 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $78.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 87% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Braidwell opened a new position in Humana worth $45.5M.

  • Braidwell's largest Q2 2026 buy was Humana: 114,500 shares worth $45.5M.
  • Braidwell added most to Alphatec Holdings in Q2 2026, an estimated $39.7M increase.
  • Braidwell's biggest Q2 2026 reduction was argenx, cutting an estimated $55.5M.
  • Braidwell fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $78.9M.
  • Braidwell's ten largest holdings make up 32% of its $2.7B portfolio in Q2 2026.
  • Braidwell opened 24 new positions and closed 23 in Q2 2026.
  • Braidwell's portfolio value fell 9.8% quarter-over-quarter to $2.7B.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.